Usana's Stock Plunge: A Cautionary Tale of Mismanaged Expectations The recent 30% decline in Usana Health Sciences stock is a stark reminder that even in an era of unprecedented corporate success, some companies are still struggling to adapt to changing market conditions.
The Utah based direct sales firm, which specializes in nutritional supplements and other health products, reported dismal second quarter earnings that left investors scrambling for answers.
Usana's woes can be attributed, in part, to its over reliance on a business model that has been under siege by shifting consumer preferences and increased regulatory scrutiny.